Randomized Phase II Study of Docetaxel plus Bevacizumab or Pemetrexed plus Bevacizumab for Elderly Non-Squamous NSCLC (TORG1323)

被引：0
|
作者：
Kozuki, Toshiyuki [1 ]
Nogami, Naoyuki [1 ]
Yamashita, Natsumi [2 ]
Shinkai, Tetsu [3 ]
Shukuya, Takehito [4 ,5 ]
Seki, Nobuhiko [6 ]
Kato, Terufumi [7 ]
Satouchi, Miyako [8 ]
Masuda, Noriyuki [9 ]
Watanabe, Koshiro [10 ]
机构：
[1] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan
[2] Natl Hosp Org, Shikoku Canc Ctr, Clin Res Ctr, Matsuyama, Ehime, Japan
[3] Shonan East Gen Hosp, Dept Internal Med, Chigasaki, Kanagawa, Japan
[4] Juntendo Univ, Fac Med, Div Resp Med, Tokyo, Japan
[5] Grad Sch Med, Tokyo, Japan
[6] Teikyo Univ, Sch Med, Dept Med Oncol, Tokyo 173, Japan
[7] Kanagawa Cardiovasc & Resp Ctr, Resp Med, Yokohama, Kanagawa, Japan
[8] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan
[9] Kitasato Univ, Sch Med, Dept Resp Med, Kanagawa, Japan
[10] Thorac Oncol Res Grp, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
elderly; Clinical Trial in Progress; NSCLC; bevacizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-085
引用
收藏
页码：S666 / S666
页数：1
相关论文
共 50 条
  • [1] Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly pts with Untreated Advanced NSCLC: TORG1323
    Ito, K.
    Hataji, O.
    Tanzawa, S.
    Harada, T.
    Fujimoto, N.
    Bessho, A.
    Takamura, K.
    Takahashi, K.
    Shinkai, T.
    Kozuki, T.
    Satouchi, M.
    Kato, T.
    Seki, N.
    Shukuya, T.
    Yamashita, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S475 - S476
  • [2] Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323
    Kozuki, Toshiyuki
    Nogami, Naoyuki
    Hataji, Osamu
    Tsunezuka, Yoshio
    Seki, Nobuhiko
    Harada, Toshiyuki
    Fujimoto, Nobukazu
    Bessho, Akihiro
    Takamura, Kei
    Takahashi, Kazuhisa
    Satouchi, Miyako
    Kato, Terufumi
    Shukuya, Takehito
    Yamashita, Natsumi
    Okamoto, Hiroaki
    Shinkai, Tetsu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (03) : 459 - +
  • [3] A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Sakamori, Yuichi
    Nagai, Hiroki
    Ozasa, Hiroaki
    Kaneda, Toshihiko
    Yoshioka, Hiroshige
    Nakagawa, Hiroaki
    Tomii, Keisuke
    Okada, Asuka
    Yoshimura, Kenichi
    Hirabayashi, Masataka
    Hirai, Toyohiro
    ANTICANCER RESEARCH, 2020, 40 (05) : 2981 - 2987
  • [4] Phase II Study of S-1 plus Bevacizumab for Pretreated Patients with Non-Squamous NSCLC
    Yamada, Kazuhiko
    Ichiki, Masao
    Takahashi, Kazuhisa
    Hisamatsu, Yasushi
    Azuma, Koichi
    Tokito, Takaaki
    Ishii, Hidenobu
    Takeoka, Hiroaki
    Shukuya, Takehito
    Nishikawa, Kazuo
    Hoshino, Tomoaki
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S661 - S661
  • [5] Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
    Yokoi, Takashi
    Torii, Yoshitaro
    Katashiba, Yuichi
    Sugimoto, Hiroyuki
    Tanijiri, Tsutomu
    Ogata, Makoto
    Inagaki, Noriko
    Kibata, Kayoko
    Hayashi, Mina
    Niki, Maiko
    Shimizu, Toshiki
    Miyara, Takayuki
    Kurata, Takayasu
    Nomura, Shosaku
    ONCOLOGY LETTERS, 2014, 8 (06) : 2453 - 2457
  • [6] Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients
    Takeoka, Hiroaki
    Yamada, Kazuhiko
    Naito, Yoshiko
    Matsuo, Norikazu
    Ishii, Hidenobu
    Tokito, Takaaki
    Azuma, Koichi
    Ichiki, Masao
    Hoshino, Tomoaki
    ANTICANCER RESEARCH, 2018, 38 (06) : 3779 - 3784
  • [7] FEASIBILITY STUDY OF PEMETREXED (PEM) PLUS BEVACIZUMAB (BV) AS THE FIRST-LINE TREATMENT FOR ELDERLY ADVANCED OR RECURRENT NON-SQUAMOUS (NON-SQ) NON-SMALL CELL LUNG CANCER (NSCLC): TORG1015.
    Kozuki, Toshiyuki
    Nogami, Naoyuki
    Kitajima, Hiromoto
    Shinkai, Tetsu
    Kato, Fumiaki
    Sakaida, Emiko
    Takiguchi, Yuichi
    Ikeda, Satoshi
    Yoshida, Masahiro
    Enomoto, Yasunori
    Kato, Terufumi
    Ogura, Takashi
    Miyamato, Shingo
    Morita, Satoshi
    Watanabe, Koshiro
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S870 - S870
  • [8] Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)
    Fukuda, Minoru
    Kitazaki, Takeshi
    Ogawara, Daiki
    Ichiki, Masao
    Mukae, Hiroshi
    Maruyama, Riichiroh
    Nakagaki, Noriaki
    Shimada, Midori
    Ikeda, Takaya
    Kishimoto, Junji
    Harada, Taishi
    Seto, Takashi
    Ebi, Noriyuki
    Takayama, Koichi
    Okamoto, Isamu
    Ichinose, Yukito
    Sugio, Kenji
    LUNG CANCER, 2019, 132 : 1 - 8
  • [9] Safety of Bevacizumab (B) in Elderly Stage IV Non-Squamous NSCLC Patients Selected by Geriatric Assessment: A Phase II Study
    Juan, Oscar
    Aparisi, Francisco
    Llorente, Mar
    Massuti, Bartomeu
    Sanchez-Hernandez, Alfredo
    Martin, Maria
    Blasco Cordellat, Sara
    Blasco, Ana
    Girones, Regina
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S916 - S916
  • [10] Phase I/II Study of Erlotinib, Carboplatin, Pemetrexed and Bevacizumab for Advanced Non-Squamous NSCLC Harboring EGFR Mutation
    Yokoi, Takashi
    Kurata, Takayasu
    Torii, Yoshitaro
    Satsutani, Naoko
    Kibata, Kayoko
    Niki, Maiko
    Nomura, Shosaku
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1219 - S1219
12345